Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtain...

Descripción completa

Detalles Bibliográficos
Autores principales: Kratochwil, Clemens, Fendler, Wolfgang P., Eiber, Matthias, Hofman, Michael S., Emmett, Louise, Calais, Jeremie, Osborne, Joseph R., Iravani, Amir, Koo, Phillip, Lindenberg, Liza, Baum, Richard P., Bozkurt, Murat Fani, Delgado Bolton, Roberto C., Ezziddin, Samer, Forrer, Flavio, Hicks, Rodney J., Hope, Thomas A., Kabasakal, Levent, Konijnenberg, Mark, Kopka, Klaus, Lassmann, Michael, Mottaghy, Felix M., Oyen, Wim J. G., Rahbar, Kambiz, Schoder, Heiko, Virgolini, Irene, Bodei, Lisa, Fanti, Stefano, Haberkorn, Uwe, Hermann, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317889/
https://www.ncbi.nlm.nih.gov/pubmed/37246997
http://dx.doi.org/10.1007/s00259-023-06255-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317889/
https://www.ncbi.nlm.nih.gov/pubmed/37246997
http://dx.doi.org/10.1007/s00259-023-06255-8

Ejemplares similares